Yahoo · Oct 31, 2026
Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.
NASDAQ · BMRN
BioMarin Pharmaceutical Inc.
Healthcare · Biotechnology
$55.66
Up+$1.47 (+2.64%)
Updated Nov 5, 2026, 12:53 AM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 10.18B
- P/E ratio
- 19.56
- Dividend yield
- 0.00%
- 52-week range
- $49.26 – $70.98
- Volume
- 4.71M
- Avg. volume
- 2.67M
Price performance · BMRN
BMRN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BMRN closed at $55.66 after 20 trading sessions, up 0.83% for the selected period.
- Last close
- $55.66
- Period change
- +0.83%
- Period low
- $54.38
- Period high
- $58.51
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $53.06 | $56.33 | $52.002 | $55.66 | 4.71M |
| Nov 2, 2026 | $58.66 | $59.51 | $57.17 | $57.44 | 3.26M |
| Oct 30, 2026 | $58.40 | $59.37 | $57.86 | $58.51 | 2.27M |
| Oct 29, 2026 | $56.58 | $57.506 | $56.29 | $57.49 | 2.62M |
| Oct 28, 2026 | $55.18 | $56.175 | $54.85 | $56.00 | 2M |
| Oct 27, 2026 | $55.83 | $56.09 | $55.0476 | $55.35 | 2.46M |
| Oct 26, 2026 | $56.50 | $56.89 | $55.34 | $55.75 | 2.36M |
| Oct 23, 2026 | $56.68 | $56.81 | $55.24 | $55.95 | 1.68M |
| Oct 22, 2026 | $55.40 | $56.91 | $55.02 | $56.63 | 2.4M |
| Oct 21, 2026 | $56.40 | $57.00 | $54.91 | $55.21 | 2.51M |
| Oct 20, 2026 | $55.08 | $56.48 | $54.95 | $56.44 | 3.47M |
| Oct 19, 2026 | $54.78 | $55.1196 | $54.075 | $54.67 | 3M |
| Oct 16, 2026 | $56.32 | $56.53 | $54.44 | $54.68 | 2.63M |
| Oct 15, 2026 | $56.45 | $57.59 | $55.955 | $56.05 | 2.92M |
| Oct 14, 2026 | $54.75 | $55.56 | $54.46 | $55.14 | 1.85M |
| Oct 13, 2026 | $55.30 | $55.655 | $53.93 | $54.38 | 2.66M |
| Oct 12, 2026 | $55.56 | $55.96 | $54.90 | $55.39 | 2.37M |
| Oct 9, 2026 | $54.80 | $55.975 | $54.48 | $54.795 | 2.15M |
| Oct 8, 2026 | $54.95 | $54.97 | $53.899 | $54.89 | 3.1M |
| Oct 7, 2026 | $56.05 | $56.60 | $54.76 | $55.20 | 2.08M |
Latest BMRN news
The latest Smart Investors Daily articles mentioning BMRN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BMRN research
Overview
Company profile and research snapshot.
Company profile
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $80.58
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2026 | Stifel | Hold | — |
| Oct 21, 2026 | Morgan Stanley | Overweight | — |
| Oct 20, 2026 | JP Morgan | Overweight | — |
| Oct 20, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 14, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease.
Benzinga · Oct 29, 2026
BioMarin Pharmaceutical Enters License Agreement With GC Biopharma And Hanmi Pharm To Develop And Commercialize Its HM15421/GC1134A Investigational Long-Acting Enzyme Replacement Therapy For Fabry Disease; Company To Pay $70M Up Front, With Partners Eligible For Up To $405M In Milestones
HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential to be the first
Yahoo · Oct 26, 2026
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to discuss third quarter 2026 financial results and provide a general business update.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
